Entity
  • Carthera

    Created in 2010
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    547 4,643
  • Activities

  • Technologies

  • Entity types

  • Location

    1 Pl. Vaclav Havel, 69007 Lyon, France

    Lyon

    France

  • Employees

    Scale: 2-10

    Estimated: 27

  • SIREN

    520004607
  • Engaged corporates

    20
    9 11
  • Added in Motherbase

    5 years, 6 months ago
Description
  • Value proposition

    Advanced Brain Therapy

    Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders.

    Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.

    By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS).

    The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

    Medical Devices, Neurosurgery, Therapeutic Ultrasound, and Neuro-oncology

  • Original language

    Advanced Brain Therapy

    Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders.

    Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.

    By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS).

    The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

Corporate interactions BETA
Corporate TypeTweets Articles
Banque Populaire Banque Populaire
Banking
Other

1 Mar 2024


EY
EY
Consulting, audit, IT Services and IT Consulting
EY
Consulting, audit, IT Services and IT Consulting
Other

1 Mar 2024


Euronext
Euronext
Finance, Financial Services
Euronext
Finance, Financial Services
Other

1 Mar 2024


Sifted
Sifted
Newspaper Publishing
Sifted
Newspaper Publishing
Other

15 Jan 2024


CNRS Innovation
CNRS Innovation
Research, Research Services
CNRS Innovation
Research, Research Services
Other

11 Jan 2024


Avolta
Avolta
Finance, Investment Banking
Avolta
Finance, Investment Banking
Other

15 Dec 2023


BFM Business
BFM Business
Media, Broadcast Media Production and Distribution
BFM Business
Media, Broadcast Media Production and Distribution
Other

3 Jul 2023


Région Auvergne-Rhône-Alpes
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration
Other

7 Jul 2023


Estimeo
Estimeo
Consulting, Information Services
Estimeo
Consulting, Information Services
Other

3 Jul 2023


La French Tech Saint-Etienne Lyon
La French Tech Saint-Etienne Lyon
French Tech, IT Services and IT Consulting
La French Tech Saint-Etienne Lyon
French Tech, IT Services and IT Consulting
Other

11 Jul 2023


Similar entities
Loading...
Loading...
Social network dynamics